<DOC>
	<DOCNO>NCT00910572</DOCNO>
	<brief_summary>Rationale : Patients diagnose hepatocellular carcinoma ( HCC ) intermediate advanced stage ( accord BCLC classification system ) amenable curative treatment . According EASL AASLD guideline patient intermediate stage HCC treat trans-arterial chemoembolization ( TACE ) patient advanced stage HCC treat molecular target drug combination accord liver function . The median survival expect patient intermediate-advanced stage range 11 20 month . Purpose Study : The purpose prospective phase II study determine whether Radioembolization Yttrium-90 microspheres ( TheraSphere® ) provide anti-tumoral effect sensible benefit term time-to-progression ( TTP ) survival patient good liver function ( Child A-B7 ) confirm diagnosis Intermediate Advanced ( presence neoplastic portal thrombosis ) Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>Radioembolization With Yttrium-90 Microspheres Intermediate Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Patients intermediate stage ( BCLC-B ) currently offer trans-arterial chemoembolisation ( TACE ) standard care . A recent meta-analysis show radioembolization beta-emitting Yttrium-90-loaded glass microspheres ( TheraSphere® ) patient HCC achieve median objective response 79 % case ( range 29-88 % ) median survival exceed 15 month report patient intermediate stage treat TheraSphere® . In patient HCC advance stage ( BCLC-C ) single treatment show statistical advantage overall survival disease progression sorafenib , provide median survival 10.7 month . Based result report literature , estimate median expect survival patient advance HCC treat TheraSphere® long 12 month . After approval July 2007 treatment protocol Y-90 compassionate use institutional IRB , National Cancer Institute Milan 40 consecutive patient treat radioembolization Yttrium-90 microspheres ( Theraspheres® ) accord guideline present prospective phase II protocol . The initial series 40 patient treat accord compassionate use Y-90 instrumental assessment procedure 's safety tolerability . The present study target 60 case include fist series 40 `` compassionate '' patient , due adherence inclusion/exclusion criterion propose phase II study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Diagnosis HCC confirm histology noninvasive criterion ( EASL/AASLD ) 2 . Intermediate stage ( BCLCB ) HCC : patient large multinodular HCC ( single HCC &gt; 5 cm multiple HCC define &gt; 3 nodule &gt; 3 cm ) , Child Pugh class A B7 cancer relate symptom ( PS=01 ) . 3 . Advanced stage ( BCLCC ) HCC : patient hepatic vascular involvement ( tumor number diameter ) , Child Pugh class A B7 , cancer relate symptom ( PS=01 ) absence extrahepatic tumor spread . 4 . Cancerrelated symptom within ECOG 01 score 5 . Liver function within Child B7 class 6 . Platelets &gt; 50.000/µL 7 . WBC &gt; 1500/µL 8 . AST/ALT &lt; 5 time upper limit normal ( U/L ) 9 . Creatinine &lt; 2.0 mg /dL 10 . No indication possible curative treatment multidisciplinary assessment ( resection , ablation , transplantation ) 11 . Signed informed consent 1 . ChildPugh class high B7 entry 2 . ECOG performance score ≥ 2 entry 3 . Tumor volume ≥ 50 % liver volume 4 . Extrahepatic tumor spread 5 . Pulmonary insufficiency 6 . Life expectancy le 3 month due HCC le 6 month due disease 7 . Previous chemoembolization procedure ( TACE ) 8 . Evidence 99mTcMAA scan vascular shunt correct angiographic coil embolization 9 . Evidence 99mTcMAA scan lung shunting , potential absorb dose radiation lung &gt; 30 Gy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Yttrium-90</keyword>
	<keyword>Radiation</keyword>
	<keyword>Radioembolization</keyword>
	<keyword>Hepatoma</keyword>
	<keyword>BCLC classification</keyword>
	<keyword>Hepatic loco-regional treatment</keyword>
	<keyword>Yttrium</keyword>
	<keyword>Microspheres</keyword>
</DOC>